Prestige Consumer Healthcare PBH North American OTC Healthcare — Cost of Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Prestige Consumer Healthcare in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Prestige Consumer Healthcare’s 10-K, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prestige Consumer Healthcare's north american otc healthcare — cost of sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prestige Consumer Healthcare's north american OTC healthcare — cost of sales?
- Prestige Consumer Healthcare (PBH) reported north american OTC healthcare — cost of sales of $113.17M in Q1 2026.
- How has Prestige Consumer Healthcare's north american OTC healthcare — cost of sales changed year-over-year?
- Prestige Consumer Healthcare's north american OTC healthcare — cost of sales increased by 5.3% year-over-year, from $107.46M to $113.17M.
- What is the long-term trend for Prestige Consumer Healthcare's north american OTC healthcare — cost of sales?
- Over 4 years (2022 to 2026), Prestige Consumer Healthcare's north american OTC healthcare — cost of sales has grown at a -0.4% compound annual growth rate (CAGR), from $419.16M to $412.7M.
- What does north american OTC healthcare — cost of sales mean?
- Represents the direct costs attributable to the production and distribution of over-the-counter healthcare products within the North American market. This includes raw materials, manufacturing labor, and logistics expenses required to bring consumer health goods to retail shelves. Monitoring this metric helps assess production efficiency and the impact of input cost inflation on segment profitability.